Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. SELLAS is a late-stage clinical biopharmaceutical company focused on novel cancer therapeutics, including its lead WT1-targeted immunotherapy GPS and its highly selective CDK9 inhibitor SLS009, and its filings offer structured insight into these programs and the company’s corporate activities.
Here, users can review current and historical Form 10-K and 10-Q reports for detailed information on SELLAS’ business, risk factors, financial condition, and research and development expenses. Form 8-K filings document material events such as quarterly financial results, warrant inducement agreements, sublease amendments for office space in New York, and outcomes of annual stockholder meetings, including director elections and advisory votes on executive compensation.
Investors interested in SELLAS’ capital structure and financing strategy can examine filings that describe warrant exercise transactions, new warrant issuances, and related registration statements on Form S-3. These documents outline the number of shares underlying various warrants, exercise prices, proceeds to the company, and any associated restrictions on future equity offerings or variable rate transactions.
Stock Titan enhances this raw filing data with AI-powered summaries that explain the key points of lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and registration statements are reflected promptly. Users can also monitor governance-related items, such as annual meeting vote results reported on Form 8-K, to track how stockholders are responding to proposals and compensation practices.
For those analyzing SLS as an investment or tracking its oncology pipeline, this page serves as a central hub to review the official regulatory record, with AI-generated highlights that make complex financial and legal language more accessible.
SELLAS Life Sciences Group, Inc. director equity grant: Director John Varian received an award of 50,000 restricted stock units on January 7, 2026. These units will vest in full on December 1, 2026, as long as he continues to serve on the company’s Board of Directors through that date. Following this award, he beneficially owns 72,900 shares of SELLAS common stock in direct ownership. The RSUs were granted at a price of $0.00 per unit, reflecting a typical non-cash equity compensation grant to a board member.
SELLAS Life Sciences Group, Inc. reported that director Robert L. Van Nostrand received an equity award in the form of 50,000 shares of common stock on January 7, 2026. The award represents restricted stock units that were granted at a price of $0.00 per share, reflecting a compensatory grant rather than a market purchase. Following this grant, Van Nostrand beneficially owns 82,900 shares of SELLAS common stock. According to the terms, the 50,000 restricted stock units will vest in full on December 1, 2026, provided he continues to serve on the company’s Board of Directors through that date.
SELLAS Life Sciences Group director David A. Scheinberg reported receiving an equity award in the form of restricted stock units. On January 7, 2026, he was granted 50,000 restricted stock units (RSUs) of the company’s common stock at a stated price of $0.00 per share, reflecting a compensatory grant rather than a purchase. According to the award terms, these RSUs are scheduled to vest in full on December 1, 2026, provided he continues to serve on the company’s Board of Directors through that date. Following this grant, he beneficially owned 73,082 shares of SELLAS common stock in total, held directly.
SELLAS Life Sciences Group, Inc. reported an equity award to a senior executive. SVP and Chief Development Officer Dragan Cicic received an award of 300,000 restricted stock units on January 7, 2026. These RSUs are scheduled to vest 25% on December 1, 2026, and 25% on each December 1 thereafter until fully vested, as long as he remains in service with the company on each vesting date. Following this grant, Cicic is shown as beneficially owning 557,805 shares of common stock, held directly. The transaction was reported at a price of $0.00 per share, reflecting the nature of the RSU award rather than a market purchase.
SELLAS Life Sciences Group, Inc. reported that its CFO, John Thomas Burns, received an award of 300,000 restricted stock units of common stock on January 7, 2026. The Form 4 shows this as an acquisition at a price of $0.00 per share, reflecting an equity compensation grant rather than an open‑market purchase.
The RSUs are scheduled to vest over four years: 25% on December 1, 2026 and 25% on each December 1 thereafter, as long as he remains in service with the company through each vesting date. After this grant, Burns is reported to beneficially own 554,327 shares of common stock, held directly.
SELLAS Life Sciences Group director Katherine Bach Kalin reported receiving 50,000 shares of common stock as a stock-based award. The Form 4 shows the transaction occurred on January 7, 2026 and was coded as an acquisition at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.
According to the disclosure, the grant represents 50,000 restricted stock units that will vest in full on December 1, 2026, provided she continues to serve on the company’s board of directors through that date. After this award, she beneficially owns 154,400 shares of SELLAS common stock, held directly.
SELLAS Life Sciences Group, Inc. director Jane Wasman reported receiving an award of 50,000 restricted stock units of common stock on January 7, 2026. The filing states that these RSUs will vest in full on December 1, 2026, provided she continues to serve on the company’s Board of Directors through that date. The award was reported at a price of $0.00 per share, reflecting a grant of equity compensation rather than a market purchase. Following this grant, she beneficially owns 92,900 shares of SELLAS common stock in direct ownership.
SELLAS Life Sciences Group, Inc. reported that it estimates unaudited cash and cash equivalents of $71.8 million as of December 31, 2025. This figure is preliminary and may change once year-end financial closing procedures and management reviews are completed. After December 31, 2025, the company received approximately $26.5 million in proceeds from the exercise of common stock warrants, adding further liquidity. As of January 7, 2026, SELLAS had 170,282,026 shares of common stock outstanding.
SELLAS Life Sciences Group, Inc. reported an insider ownership change by its Chief Financial Officer, John Thomas Burns. On 12/03/2025, the company withheld 58,592 shares of common stock at $1.5 per share to cover the CFO’s tax withholding obligations related to vesting Restricted Stock Units. This reduced his holdings but did not involve an open-market sale. Following the transaction, Burns beneficially owns 254,327 shares of SELLAS common stock directly.